Oncology Conference - 2021 Updates in Treatment Strategies for the Management of Breast Cancer

This accredited continuing education activity “2021 Updates in Treatment Strategies for Management of Triple Negative Breast Cancer”, is recorded from the live webinar held on 2/13/2022.

If you participated in the live webinar titled - 2021 Updates in Treatment Strategies for Management of Triple Negative Breast Cancer on 2/13/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 2/13/2022. However, you may enroll in this activity to review the contents.

2021 Updates in Treatment Strategies for Management of Triple Negative Breast Cancer is a CME-accredited oncology webinar that features leading experts in breast cancer who will provide a comprehensive overview of current and emerging strategies for management of triple-negative breast cancer. The goal of this activity is to improve the knowledge, competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with triple negative breast cancer. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for triple-negative breast cancer. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee)

If you are a healthcare provider involved in patient care and you are not employed by the Industry, then you don't pay anything to register for this activity.

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting associated with this webcast and wish to register for this enduring material please contact us and we will register you for free.

Target Audience

Cancer care professionals including:

Practicing oncologists
Oncology fellows
Oncology nurses
Oncology nurse practitioners
Oncology physician assistants
Oncology pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

Review frequent molecular abnormalities in triple-negative breast cancer, and appropriate timing of testing to detect these abnormalities.
Outline efficacy and toxicities of immune checkpoint inhibitors, PARP inhibitors, Trop-2inhibitors, and other chemotherapy agents in management of triple-negative breast cancer.
Identify the role of neoadjuvant and adjuvant systemic therapy options in curative-intent treatment of triple-negative breast cancer, including the role of chemotherapy, immune checkpoint inhibitors and PARP inhibitors.
Incorporate appropriate sequencing of treatment options in patients with metastatic triple-negative breast cancer.
Integrate emerging evidence in precision oncology into treatment paradigms for treatment of triple-negative breast cancer.

Course summary

Available credit:

2.50 ABIM MOC II
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
2.50 AMA PRA Category 1 Credit™
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
2.50 Nursing Contact Hours
Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.50 Contact Hours.

Course opens:

03/07/2022

Course expires:

03/07/2023

Cost:

$1.00

This educational activity features recorded videos from the live webinar titled - 2021 Updates in Treatment Strategies for the Management of Breast Cancer held 2/13/2022.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.

28 minutes: Immune-Checkpoint Inhibitors in Management of Triple-Negative Breast Cancer - Roberto Leon Ferre, MD

17 minutes: Germline Genetic Testing and PARP Inhibitors in Management of Triple-Negative Breast Cancer - Neelam Desai, MD

25 minutes: Q&A Session - Raghunadharao Digumarti, MBBS, MD, DM, FRCP (London), FACP, Xiaowen Wang, MD, PhD, Sudip Shrestha, MD

15 minutes: Efficacy and Toxicities of Sacituzumab Govitecan in Management of Metastatic Triple-Negative Breast Cancer - Neelima Vidula, MD

30 minutes: NGS, ctDNA and Other Precision Approaches for Identification of Novel Therapies in Management of Triple-Negative Breast Cancer - Christos Vaklavas, MD

35 minutes: Q&A Session - Xiaowen Wang, MD, PhD, Sudip Shrestha, MD

Speaker/Topic Presenter(s)